leadf
logo-loader
viewHavn Life

Havn Life Sciences to take its magic-mushroom growing firm public this summer

Havn Life Sciences Inc Co-CEO Susan Chapelle tells Proactive the privately-held Vancouver-based biotechnology company is looking to take its magic mushroom-focused firm public, expecting to launch its IPO this summer.

Chapelle says what's more, the firm is progressing with its research in growing psilocybin mushrooms to help fix the restrictive supply-chain issue some firms conducting clinical studies are facing in this space.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Tiziana Life Sciences: Delivery method & data 'looks promising' ahead of...

Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) has announced plans to begin a clinical study of its nasally administered Foralumab in COVID-19 patients in Brazil. Proactive analyst Emma Ulker talks to Katie Pilbeam about the trial which will begin shortly with clinical data potentially...

35 minutes ago

2 min read